Visikol’s Director of Drug Discovery, Peter Worthington Ph.D.,
to Present at
SELECTBIO’s 3D-Cell Culture, Organoids, and Organs-on-Chips Conference
Balancing Cost, Throughput and In Vivo Relevancy for In Vitro Liver Studies
Wednesday, 15 December 2021 at 14:00
While we can generate ever more complex advanced cell culture models for use in our in vitro programs, not all research questions require this level of complexity. Through this presentation, Dr. Worthington will discuss how to balance cost, throughput and in vivo relevancy in the context of drug induced liver injury (DILI) and modeling liver disease (NASH, NAFLD). The presentation will review the use cases and applications for 2D cell culture models, 3D spheroid models and ex vivo precision cut tissue slice model
|
